Category: SeaPRwire

SHENZHEN, Jan 24, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual. IL-4Rα is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis (AD), asthma, prurigo nodularis, etc. Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, MG-K10 allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4Rα monoclonal antibody marketed in China. Currently marketed anti-IL-4Rα drugs require dosing every two weeks, whereas MG-K10 only requires dosing every four weeks, demonstrating good efficacy and safety. MG-K10 has the potential to be the Best-in-Class (BIC). This collaboration marks another significant milestone for Dermavon (formerly known as CMS Skinhealth)’s layout in the dermatology field. MG-K10 will enrich the global differentiated innovative pipeline of Dermavon, and will strongly synergize with the existing product portfolio, such as marketed innovative drug ILUMETRI (tildrakizumab injection), marketed exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and dermatology-grade skincare products of Heling soothing product series (developed for AD patients), and innovative pipeline drugs ruxolitinib cream (for the topical treatment of mild to moderate AD and non-segmental vitiligo) and povorcitinib (for the treatment of non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis and chronic spontaneous urticaria), etc. Leveraging its proven clinical development and commercialization capabilities, the Group will fully cooperate with Mabgeek Biotechnology to promote the approval of MG-K10 in China, bringing a new treatment option with lower dosing frequency, good efficacy and safety to patients with type 2 inflammatory diseases in China. More information about MG-K10 MG-K10 is a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection that used for the treatment of type 2 inflammatory diseases, including AD, asthma, prurigo nodularis, allergic rhinitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease and so on. It holds substance patents in specific countries/regions within the Territory. MG-K10 has entered Phase III clinical trials in China for AD, asthma, and prurigo nodularis. In the completed Phase II clinical trials for adult moderate-to-severe AD and moderate-to-severe asthma, MG-K10 has demonstrated good efficacy and safety[1-2]. Additionally, MG-K10 has obtained IND approval for eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis in China. According to Frost & Sullivan, the global market for treatments targeting IL-4Rα is expected to reach US$28.7 billion by 2030, with a compound annual growth rate (CAGR) of 21.8% from 2020 to 2030. In China, the market is projected to reach US$4.08 billion by 2030, with a CAGR of 76.8% from 2020 to 2030. About AD indication MG-K10’s first indication, AD, is a chronic inflammatory skin condition characterized by severe itching. It is the most burdensome non-fatal skin disease globally, with at least 230 million people affected worldwide[3]. AD is also a prevalent and high-burden chronic disease in China, with the prevalence showing an upward trend[3]. According to the Global Burden of Disease Study 2019, the number of AD patients in China increased by 25.65% from 1990 to 2019[3]. It is estimated that there are approximately 36.09 million AD patients in China[3], with approximately 9.625 million suffering from moderate-to-severe AD[4]. Current treatment options for AD primarily include topical and systemic treatments. For moderate-to-severe AD, topical medications are often insufficient to achieve disease control, necessitating the initiation of systemic treatments. However, due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate-to-severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[3]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About Mabgeek Biotechnology Mabgeek Biotechnology was founded in 2016 and has always adhered to the research and development concept of “innovation, efficiency and safety”, focusing on the fields of allergic inflammatory diseases and autoimmune diseases. Mabgeek Biotechnology is equipped with a research and development team composed of top industry experts. With excellent research capabilities and deep industry experience, Mabgeek Biotechnology uses its unique TEADA high-throughput antibody screening platform to develop innovative antibody drugs with high biological activity, excellent druggability, and differentiation. Mabgeek Biotechnology is committed to providing safer, more effective and more convenient treatment solutions for patients worldwide. For more information about Mabgeek Biotechnology and its products, please visit: https://www.mabge.com/. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Reference: The data of the product’s Phase II clinical trial for AD indication as disclosed by Mabgeek: https://www.mabge.com/en/index.php?c=show&id=23 The interim data of the product’s Phase II clinical trial for asthma indication as disclosed by Mabgeek: https://www.mabge.com/index.php?c=show&id=18 Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. Mao, Dandan et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chinese medical journal vol. 136,5 604-606. 5 Mar. 2023, DOI:10.1097/CM9.0000000000002560 CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

SHENZHEN, CHINA – January 08, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party. As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety profile to improve compliance of patients and therefore brings clinical benefits. CMS has rooted in the central nervous system therapeutic fields for years, continuously deploying and developing global differentiated and innovative products to strengthen its competitiveness in its advantageous specialty therapeutic fields. ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with various central nervous system products including the marketed innovative drug VALTOCO (diazepam nasal spray), the original branded drug Deanxit (flupentixol and melitracen tablets) and the innovative pipeline drug Y-3 injection (a novel brain cytoprotectant that treats stroke). Leveraging its proven clinical development capability and compliant commercialization system with high efficiency, CMS will promote the approval of ZUNVEYL in China as soon as possible to bring a new drug option for the treatment of cognitive impairment in Alzheimer’s disease patients. About ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. Patent in regard to use of ZUNVEYL has already been granted in China. About Alzheimer’s disease Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future. Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, suggesting that Alzheimer’s disease patients still have an urgent need for safer therapies. About ALPHA Alpha is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive impairment with mild Traumatic Brain Injury. On July 2024, Alpha received approval by the FDA of its New Drug Application (NDA) for ZUNVEYL for the treatment of mild-to-moderate Alzheimer’s disease. Alpha will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation. Additionally, Alpha has three pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation for the treatment of mild-to-moderate Alzheimer’s disease, ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild Traumatic Brain Injury. For more information about Alpha and its pipeline, please visit: https://www.alphacognition.com/ . About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Reference: Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832 Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.003 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004 Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7 Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103 Research Report on the Diagnosis and Treatment of AD Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

Taipei - January 07, 2025 - (SeaPRwire) - 為進一步簡化臺灣旅客前往菲律賓的簽證程式，知名簽證服務機構OntrailVisa宣佈推出針對臺灣居民的菲律賓eTravel電子入境卡申請服務。這項服務通過優化的流程設計和多語言支援，為臺灣護照持有人提供無縫的線上體驗。 菲律賓eTravel電子入境卡的重要性 根據菲律賓官方規定，所有旅客在進入和離開菲律賓之前，均需完成菲律賓eTravel電子入境卡的註冊。此數位平臺旨在收集旅客的基本資訊，以加速邊境通關流程。 然而，對於不熟悉英文或流程的臺灣旅客而言，註冊過程可能充滿挑戰。OntrailVisa順應需求，開發了一套專為臺灣居民設計的申請服務，為使用者提供翻譯為繁體中文的表格、全面的申請指導以及全天候客戶支援，説明旅客輕鬆完成註冊並享受無憂出行體驗。 服務亮點：為什麼選擇OntrailVisa？ 易於理解的中文支持 OntrailVisa特別將菲律賓eTA申請表格翻譯成繁體中文，説明臺灣旅客克服語言障礙，輕鬆完成填寫。同時，直觀的使用者介面和簡化的表格設計，也大幅降低了填寫錯誤的風險。 專業協助貫穿全程 申請過程中，OntrailVisa團隊會提供即時提示，指導使用者正確提交所需資訊，顯著降低被拒風險。遇到任何疑問，用戶可隨時聯繫24小時線上的客戶支援團隊。 高效處理時間 OntrailVisa承諾在收到完整材料後，1至2天內處理完畢並提交申請，為急需出行的旅客節省時間。此外，服務還提供全額退款保證，若申請被拒，用戶僅需聯繫平臺即可獲得退款。 用戶體驗第一的全面優化 從自動驗證功能到專家審核流程，OntrailVisa的技術和人工支援相輔相成，確保每位旅客的申請準確無誤，避免因疏忽造成的錯誤或延誤。 旅客的真實體驗：輕鬆申請無後顧之憂 為了驗證服務效果，OntrailVisa採訪了多位使用平臺申請菲律賓eTravel的旅客，其中包括臺灣居民莊先生（Mr. Zhuang）。他表示：“我原本擔心申請過程會很複雜，但OntrailVisa讓這一切變得簡單。尤其是中文支援，讓我填寫表格時完全沒有壓力。我很高興選擇了這個平臺。” 莊先生的經歷僅是眾多用戶滿意評價中的一個例子，體現了OntrailVisa在提供卓越服務上的專業能力。 關於OntrailVisa OntrailVisa是一家專為臺灣護照持有人提供旅行簽證解決方案的機構，致力於為旅客簡化複雜的申請流程。無論是申請前往菲律賓、美國還是越南的簽證，OntrailVisa都能提供精准指導和全方位支援。 此外，OntrailVisa還通過其官方網站 提供詳細的簽證要求和申請指南，方便使用者隨時瞭解最新資訊。 作為一家以客戶為中心的企業，OntrailVisa的使命是通過可靠的資訊、先進的技術和專業的團隊支持，幫助旅客在繁忙的行程安排中節省時間、避免壓力。 規劃您的菲律賓之旅，從OntrailVisa開始 菲律賓作為臺灣旅客熱門的旅行目的地，以其豐富的自然景觀和多樣的文化吸引著無數遊客。如今，通過OntrailVisa的菲律賓eTravel服務，旅客們可以更專注於計畫行程，無需為複雜的簽證手續而擔憂。 訪問OntrailVisa官網瞭解更多詳情，讓您的旅行計畫輕鬆啟程。 OntrailVisa，旅行無憂的最佳選擇。 媒體聯絡 電子郵件：info@ontrailvisa.tw 官網：https://www.ontrailvisa.tw/philippines

Brasília, Brazil – January 07, 2025 – (SeaPRwire) – Kess Energy, a leading junior lithium miner based in Brasília, Brazil is proud to announce the launch of a ground-breaking organization, “Comunidades Avança Brasil” or Communities Forward Brazil (CFB), aimed at ensuring that the economic and social benefits of Brazil’s flourishing lithium mining boom are rapidly and equitably shared with local communities impacted by disruptive operations. The Brazilian lithium sector is experiencing an unprecedented expansion, driven by surging global demand for renewable energy solutions and electric vehicle technologies. While the industry has brought significant economic opportunities, there remains an urgent need to translate these gains into tangible improvements in the lives of communities living near mining sites. “Mining is a transformative force in our economy, but its true success lies in its ability to uplift the people and communities most affected by our activities,” said Inato Ramirez, Chairman of Kess Energy. “Through Communities Forward Brazil, we aim to work collaboratively with industry peers, local governments, and NGOs to create actionable solutions that address local needs—from infrastructure and education to health and environmental conservation.” Communities Forward Brazil’s key objectives include: Community engagement: Establishing open dialogue forums to listen to the concerns and aspirations of local residents. Fair redistribution of benefits: Advocating for policies that ensure a greater share of mining revenues is reinvested in local community projects. Sustainability and innovation: Partnering with stakeholders to implement environmentally sustainable practices that balance development with ecological preservation. Transparency and accountability: Promoting ethical business practices and transparent communication regarding mining activities and their impact. Kess Energy invites other mining industry players to join Communities Forward Brazil in creating a unified platform to champion sustainable development and community empowerment. “By joining forces, I think it’s possible that we can redefine the narrative of mining in Brazil,” added Mr. Ramirez. “Our goal is to ensure the legacy of the lithium boom is not only wealth creation for big business and shareholders but also the elevation of the communities who are the heart and soul of our nation.” About Kess Energy Kess Energy is a junior lithium mining company dedicated to meeting the increasing global demand for lithium through responsible and sustainable mining practices that respect and consider the needs of the communities in which its assets are located. With a portfolio of high-quality lithium assets and a commitment to innovation, Kess Energy is well-positioned to play a pivotal role in the energy transition while enabling communities to share in the commercial benefits of its business. Please contact +55 61 4042 9257 or visit our office at Centro Empresarial Varig, SCN QUADRA 04 BL B – Asa Norte, Brasília – DF, 70714-900, Brazil. Media Contact Brand: Kess Energy Contact: Joseph Hera Email: contact@kessenergy.com Website: https://kessenergy.com

New Delhi, India – January 01, 2025 – (SeaPRwire) – Capital Revo, a leading company in the financial services industry, is excited to announce that it has won the “Innovation in Forex Trading Platform“ for Excellence in Financial Services. This award recognizes Capital Revo’s exceptional contributions to the industry and its commitment to providing outstanding service to its clients. Leading in finance innovation Capital Revo one of the largest global players in fintech, financial services and online trading. In addition to an efficient user experience, high-quality relationship management, and excellent customer support, Capital Revo offers traders, institutional investors and brokers worldwide access to deep institutional liquidity and advanced trading technology, combined with an efficient user experience, high-quality relationship management and excellent customer support. These services include investment management, financial planning, wealth management, and advisory services. By combining the latest technology with personalized service, Capital Revo has set a high standard in the industry. “We are thrilled to receive this award,” said the team of Capital Revo. “It reflects the hard work and dedication of our team. Our goal has always been to provide our clients with the best financial strategies and solutions, and this recognition inspires us to keep striving for excellence.” Client Focus The focus on clients is one of the things that has contributed to Capital Revo’s success. The organization considers it vital to understand the particular financial objectives and challenges of each customer in order to provide effective solutions. By creating strong relationships with customers and maintaining open communication, Capital Revo ensures that its clients are confident about their investment choices. “Our clients are at the core of everything we do”. “Their trust and happiness motivate us. This award is not only a tribute to our hard work but also a celebration of our customers’ accomplishments.” Leader among Competitors Winning the award for Excellence in Financial Services for our platform innovation, is an important achievement for Capital Revo. It highlights the firm’s industry-leading position in finance, as well as its commitments to upholding high standards of honesty, trustworthiness and innovativeness. The forward-looking nature and commitment to continuous improvement by Capital Revo have made it highly reputed among clients and peers within the same industry. About Capital Revo Capital Revo has grown into a global market leader in the FinTech, financial services and online trading industry. Capital Revo offers traders, institutional investors and brokers worldwide access to deep institutional liquidity and advanced trading technology, combined with an efficient user experience, high-quality relationship management and excellent customer support. The company’s mission is to help clients achieve their financial goals through expert guidance and exceptional service. For more information about Capital Revo and its award-winning services, please visit https://capitalrevo.com/ Social Links Instagram: https://www.instagram.com/capital_revo/ Facebook: https://www.facebook.com/people/Capital-Revo/61552517622119/ Media contact Brand: Capital Revo Contact: Media team Email: marketing@capitalrevo.com Website: https://capitalrevo.com SOURCE: Capital Revo The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...